Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry co
- PDF / 335,462 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 113 Downloads / 190 Views
ORIGINAL ARTICLE
Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM) Alonso Ricardo 1,2,3 & Quarracino Cecilia 3,4 & Eizaguirre Bárbara 1,3 & Cohen Leila 1,3 & Silva Berenice 1,3 & Pita Cecilia 1,3 & Rojas Juan Ignacio 3,5 & Agustín Pappolla 3,5 & Jimena Miguez 3,5 & Liliana Patrucco 3,5 & Edgardo Cristiano 3,5 & Vrech Carlos 3,6 & Volman Gabriel 3,7 & Silva Emanuel 3,8 & Barboza Andres 3,9 & Deri Norma 3,10 & Tkachuk Verónica 3,11 & Zanga Gisela 3,12 & Tavolini Dario 3,13,14 & Saladino María Laura 3,15 & Luetic Geraldine 3,16 & Menichini María Laura 3,16 & Carnero Contentti Edgar 3,17 & López Pablo 3,17 & Steinberg Judith 3,18 & Divi Pablo 3,19 & Hryb Javier 3,20 & Alves Pinheiro Amelia 3,21 & Carra Adriana 3,17,22 & Balbuena María Eugenia 3,11 & Lázaro Luciana 2,3 & Fernández Liguori Nora 2,3 & Garcea Orlando 1,3 & on behalf of RelevarEM investigators Received: 23 May 2020 / Accepted: 7 August 2020 # Fondazione Società Italiana di Neurologia 2020
Abstract Background Primary progressive multiple sclerosis (PPMS) is an infrequent clinical form of multiple sclerosis (MS). Scarce information is available about PPMS in Latin America. The aim of this work is to describe the clinical and demographic characteristics of PPMS patients in Argentina. Material and methods RelevarEM is a longitudinal, strictly observational registry in Argentina. Clinical and epidemiological data from PPMS patients were described. Results There were 144 cases of PPMS. They represented 7% of MS patients. The mean age was 44.1 years. The female:male ratio was 1.08. The mean Expanded Disability Status Scale (EDSS) score was 5.5 and the mean disease evolution time was 10.6 years. Oligoclonal bands were found in 72.9%. At the time of diagnosis, magnetic resonance imaging showed spinal cord lesions in 82.6% and contrast-enhancing brain lesions in 18.1% of patients. Almost one third of patients were treated with a diseasemodifying drug, and ocrelizumab was the most frequently used (55.8%). Conclusions PPMS is an infrequent subtype of MS and its recognition is of the highest importance as it has its own evolution, treatment, and prognosis. The importance of our research resides in providing local data and contributing to a better understanding of PPMS and its treatment in Latin America. Keywords RelevarEM . Primary progressive multiple sclerosis . Argentinean multiple sclerosis epidemiology
Introduction Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and neurodegenerative disease that affects the central nervous system (CNS) with a variable evolution course. Its complex pathogenicity involves demyelination, axonal loss, and reactive gliosis, among other mechanisms [1]. It is the main non-traumatic cause of neurological disability in young
* Alonso Ricardo [email protected] Extended author information available on the last page of the article
adults, with a peak incidence between 18 and 50 years of age. In many countries, includin
Data Loading...
